Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cance...
Eli Lilly and Company (NYSE: LLY) announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics Licen...
OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer&...
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorex...
Duality Biologics ("DualityBio"), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjuga...
Beyond Cancer, Ltd., a clinical-stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors...
Amarna Therapeutics, (“Amarna” or “the Company”), a privately held biotechnology company specializing in transformative gene therap...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthroug...
Polyrizon Ltd. (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, anno...
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy t...
The competition among three TROP2 antibody-drug conjugates is entering a new stage as Kelun-Biotech’s Merck & Co.-partnered sacituzumab...
Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. ("Trav...
© 2025 Biopharma Boardroom. All Rights Reserved.
